Skip to content
Screener

Glaukos GKOS Q4 2025 Annual earnings

Reported February 17, 2026 · After market close

Revenue$143.1MBeat by $6.7M
EPS-$0.28Miss by $0.06
Revenue estimate$136.4M
EPS estimate-$0.22

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$167.9M
EPS estimate-$0.12

Financials

Q4 2025

Income statement

See full
Revenue$143.1M+35.7%
Gross profit--100%
Operating income-$139.9M-388%
Net income-$133.7M-298%
EPS (diluted)-$2.33-295%

Balance sheet

See full
Cash & equivalents$90.8M-46.5%
Total debt$106.5M+0.6%
Total equity$656.2M-14.4%
Total assets$893.5M-8.3%

Cash flow

See full
CapEx$2.9M+68.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$6.48B-21.6%
Enterprise value$6.5B-20.8%
P/S12.8×-8.8×

Profitability

See full
Gross margin56%-19.5pp
Operating margin-39.3%+11.9pp
Net margin-37%-1.1pp

Returns & leverage

See full
Return on equity-26.4%+3.2pp
Debt / equity0.2×0.0×
Current ratio4.7×-1.3×

Segments

By product

See full
Glaucoma$119.2M+41.6%
Corneal Health$24.0M+12.2%

By segment

See full
Development And Commercialization Of Ophthalmic Therapies$143.1M+35.7%

FAQ

When did Glaukos report Q4 2025 earnings?
Glaukos (GKOS) reported Q4 2025 earnings on February 17, 2026 after market close.
What were Glaukos's Q4 2025 revenue and EPS?
Glaukos reported revenue of $143.1M and eps of $-0.28 for Q4 2025.
Did Glaukos beat estimates in Q4 2025?
Revenue beat the consensus estimate of $136.4M by $6.7M. EPS missed the consensus estimate of $-0.22 by $0.06.
How did Glaukos's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 35.7% from $105.5M a year earlier and eps grew 30.0% from $-0.40.
Where can I find Glaukos's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-016410) and the 10-K periodic report (0001193125-26-061944) directly on SEC EDGAR. The filing index links above go to sec.gov.